RIIGL - Inhibitorpeptid von Amyloid-beta

RIIGL - Inhibitorpeptid von Amyloid-beta

Artikel-Nr.: P2257.7005

Shipping: shipped at RT, store at -20°C

Sofort versandfertig, Lieferzeit 1-2 Werktage

171,36 € *


Wählen Sie bitte die gewünschte Packungsgröße aus.


Wählen Sie bitte die gewünschte Reinheit aus.

RIIGL is one of several inhibitors of amyloid-beta aggregation that have been published. Many of... mehr
Produktinformationen "RIIGL - Inhibitorpeptid von Amyloid-beta"

RIIGL is one of several inhibitors of amyloid-beta aggregation that have been published. Many of them are fragments and modified peptides derived from the native amyloid-beta sequence. Others were identified by phage display approaches. An overview about peptides that target amyloid-beta is described by Stains et al. (2007) ChemMedChem 2, 1674-1692.

Characteristic of Alzheimer disease is the accumulation of amyloid plaques (amyloid-beta) in the brain. The major components of these plaques are 36-42 residue-long amyloid-beta-peptides, which form insoluble fibrils via self-assembly.
The amyloid-beta-peptides are fragments of the broadly distributed, membrane-bound amyloid precursor protein APP, encoded on chromosome 21. They are formed from the proteolytic cleavage of APP by ß- and γ-secretases.
One of the most common and intensively studied amyloid ß isoforms is amyloid ß1-40), which is present in amyloid plaques.

M. Ahmed, J. Davis, D. Aucoin, T. Sato, S. Ahuja, S. Aimoto, J. I. Elliott, W. E. Van Nostrand, S. O. Smith (2010) Nat. Struct. Mol. Biol. 17, 561-567.
T. Hartmann, S. C. Bieger, B. Brühl, P. J. Tienari, N. Ida, D. Allsop, G. W. Roberts, C. L. Masters, C. G. Dotti, K. Unsicker, K. Beyreuther (1997) Nat. Med. 3, 1016-1020.

Amyloid-ß-peptides and innate immunity
In Alzheimer’s disease, deposition of amyloid-beta triggers a protracted sterile inflammatory response. Chronic stimulation of the innate immune system is believed to underlie the pathology of this disease. It was shown, that amyloid-beta triggers inflammatory signalling through a heterodimer of Toll-like receptors 4 and 6. Assembly of this recently identified heterodimer is regulated by signals from the scavenger receptor CD36, CD36-TLR4-TLR6 activation was identified as a common molecular mechanism by which atherogenic lipids and amyloid-beta stimulate sterile inflammation (Stewart et al. 2010, Nature Immunology 11, 155-161 doi:10.1038/ni.1836).

Related products:
P2255 - Amyloid-beta (16-20) - KLVFF >
P2304 - Amyloid-beta (10-20) - YEVHHQKLVFF >
P2250 - Amyloid-beta (1-40) human - DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV - HCl salt peptide >
P2248 - Amyloid-beta (1-40) rat - DAEFGHDSGFEVRHQKLVFFAEDVGSNKGAIIGLMVGGVV - HCl salt peptide >

Weitere Artikel passend zu "RIIGL - Inhibitorpeptid von Amyloid-beta"
Specifications: Sequence: RIIGL Purity: >70% / >95% (HPLC) Appearance: lyophilized,... mehr

Technische Daten:

Sequence: RIIGL
Purity: >70% / >95% (HPLC)
Appearance: lyophilized, white powder


study of Alzheimer desease Fibrilization, fibrillogenesis studies



Sicherheits Hinweise / Safety

Klassifizierungen / Classification

eclass-Nr: 32-16-04-09
Dokumente - Protokolle - Downloads mehr

Dokumente - Protokolle - Downloads

Hier finden Sie Informationen und weiterführende Literatur zu RIIGL - Inhibitorpeptid von Amyloid-beta. Für weitere Dokumente (Zertifikate mit weiteren Lotnummern, Sicherheitsdatenblätter in anderer Sprache, weitere Produktinformationen) wenden Sie sich bitte an Genaxxon biosience unter: info@genaxxon.com oder Tel.: +49 731 3608 123.